Recent clinical trials have demonstrated that incorporating immune checkpoint inhibitors (ICIs) into NAC enhances the rate of pCR in patients with early-stage, HG III, ER + HER2- breast cancer [14, 15]. Here, ERBB2 is linked to breast cancer.